Inclisiran prescribing information
Pro Research Analysisby 
Searched over 200M research papers
Inclisiran Prescribing Information: Indications and Patient Selection
Inclisiran is a small interfering RNA (siRNA) medication that targets hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to significant reductions in low-density lipoprotein cholesterol (LDL-C) levels. It is approved as an adjunct to diet and statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering. Inclisiran is also indicated for primary prevention in patients with high LDL-C and no history of cardiovascular disease 134.
Dosing Schedule and Administration Guidelines
Inclisiran is administered by a healthcare professional as a subcutaneous injection. The recommended dosing schedule is an initial dose, a second dose at 3 months, and then every 6 months thereafter. This twice-yearly dosing is a key advantage, offering improved patient compliance compared to more frequent dosing regimens of other lipid-lowering agents 134.
If a scheduled dose is missed by less than 3 months, it should be administered as soon as possible, and the regular schedule should be continued. If the dose is missed by more than 3 months, the dosing schedule should be restarted .
Efficacy: LDL-C Reduction
Clinical trials and real-world data consistently show that inclisiran reduces LDL-C by approximately 50% when used as prescribed, with effects observed across different patient populations, including those with ASCVD and HeFH 123. In patients who did not discontinue background lipid-lowering therapy or switch from a PCSK9 monoclonal antibody, LDL-C reductions of about 50% were observed, mirroring results from clinical trials .
Safety and Side Effects
Inclisiran has a favorable safety profile. Reported side effects are generally mild and include injection site pain, fever, and, rarely, paresthesia or swelling. Serious adverse events leading to discontinuation are uncommon 26. Ongoing monitoring and patient education about potential side effects are recommended 46.
Insurance Approval and Access
Insurance approval rates for inclisiran vary. Patients with Medicare are much more likely to receive approval compared to those with non-Medicare insurance. In several real-world studies, 100% of Medicare patients obtained access, while approval rates for non-Medicare patients were significantly lower 125. This disparity affects younger patients and those with HeFH more than older patients with ASCVD 125.
Improving Adherence and Clinic-Based Administration
Team-based care and dedicated clinics for inclisiran administration have been shown to improve adherence and facilitate monitoring for side effects. These clinics coordinate scheduling, insurance approval, and patient education, resulting in higher rates of patients staying on schedule with their injections .
Conclusion
Inclisiran is an effective, safe, and convenient option for LDL-C lowering in adults with ASCVD, HeFH, or high LDL-C requiring additional therapy. Its twice-yearly dosing supports better adherence, though insurance approval remains a barrier for some patients, particularly those without Medicare. Clinic-based administration and coordinated care models can further enhance patient outcomes and adherence to therapy 1234+2 MORE.
Sources and full results
Most relevant research papers on this topic